Golden has been acquired by ComplyAdvantage.Read about it here ⟶

List of patents in the Genetic engineering industry

Patents where

Current Assignee

Industry

Name	Description	Patent Applicant	Current Assignee	Patent Jurisdiction	Patent Number	Date of Patent
‌ US Patent 11887696 Systems and methods for classifying, prioritizing and interpreting genetic variants and therapies using a deep neural network	Patent 11887696 was granted and assigned to Deep Genomics (company) on January, 2024 by the United States Patent and Trademark Office.	Deep Genomics	Deep Genomics	United States Patent and Trademark Office	11887696	January 30, 2024
‌ US Patent 11568960 Neural network architectures for scoring and visualizing biological sequence variations using molecular phenotype, and systems and methods therefor	Patent 11568960 was granted and assigned to Deep Genomics (company) on January, 2023 by the United States Patent and Trademark Office.	Deep Genomics	Deep Genomics	United States Patent and Trademark Office	11568960	January 31, 2023
‌ US Patent 10155027 Alpha-galactosidase A and 1-deoxygalactonojirimycin co-formulation for the treatment of fabry disease	Patent 10155027 was granted and assigned to Amicus Therapeutics on December, 2018 by the United States Patent and Trademark Office.	Amicus Therapeutics	Amicus Therapeutics	United States Patent and Trademark Office	10155027	December 18, 2018
‌ US Patent 10076514 Methods of treating fabry disease in patients having the G9331A mutation in the GLA gene	Patent 10076514 was granted and assigned to Amicus Therapeutics on September, 2018 by the United States Patent and Trademark Office.	Amicus Therapeutics	Amicus Therapeutics	United States Patent and Trademark Office	10076514	September 18, 2018
‌ US Patent 11833164 Methods of treating Fabry disease in patients having a mutation in the GLA gene	Patent 11833164 was granted and assigned to Amicus Therapeutics on December, 2023 by the United States Patent and Trademark Office.	Amicus Therapeutics	Amicus Therapeutics	United States Patent and Trademark Office	11833164	December 5, 2023
‌ US Patent 11623916 Highly purified batches of pharmaceutical grade migalastat and methods of producing the same	Patent 11623916 was granted and assigned to Amicus Therapeutics on April, 2023 by the United States Patent and Trademark Office.	Amicus Therapeutics	Amicus Therapeutics	United States Patent and Trademark Office	11623916	April 11, 2023
‌ US Patent 10251873 Methods of treating fabry patients having renal impairment	Patent 10251873 was granted and assigned to Amicus Therapeutics on April, 2019 by the United States Patent and Trademark Office.	Amicus Therapeutics	Amicus Therapeutics	United States Patent and Trademark Office	10251873	April 9, 2019
‌ US Patent 10537564 Methods of treating fabry disease in patients having the G9331A mutation in the GLA gene	Patent 10537564 was granted and assigned to Amicus Therapeutics on January, 2020 by the United States Patent and Trademark Office.	Amicus Therapeutics	Amicus Therapeutics	United States Patent and Trademark Office	10537564	January 21, 2020
‌ US Patent 10185803 Systems and methods for classifying, prioritizing and interpreting genetic variants and therapies using a deep neural network	Patent 10185803 was granted and assigned to Deep Genomics on January, 2019 by the United States Patent and Trademark Office.	Deep Genomics	Deep Genomics	United States Patent and Trademark Office	10185803	January 22, 2019
‌ US Patent 9873894 Methods and compositions for treatment of a genetic condition	Patent 9873894 was granted and assigned to Sangamo Therapeutics on January, 2018 by the United States Patent and Trademark Office.		Sangamo Therapeutics	United States Patent and Trademark Office	9873894	January 23, 2018
‌ US Patent 10357548 α-galactosidase A and 1-deoxygalactonojirimycin co-formulation	Patent 10357548 was granted and assigned to Amicus Therapeutics on July, 2019 by the United States Patent and Trademark Office.	Amicus Therapeutics	Amicus Therapeutics	United States Patent and Trademark Office	10357548	July 23, 2019
‌ US Patent 9580727 Compositions and methods of engineered CRISPR-Cas9 systems using split-nexus Cas9-associated polynucleotides	Patent 9580727 was granted and assigned to Caribou Biosciences on February, 2017 by the United States Patent and Trademark Office.	Caribou Biosciences	Caribou Biosciences	United States Patent and Trademark Office	9580727	February 28, 2017
‌ US Patent 9745600 Compositions and methods of engineered CRISPR-Cas9 systems using split-nexus Cas9-associated polynucleotides	Patent 9745600 was granted and assigned to Caribou Biosciences on August, 2017 by the United States Patent and Trademark Office.	Caribou Biosciences	Caribou Biosciences	United States Patent and Trademark Office	9745600	August 29, 2017
‌ US Patent 9970026 Compositions and methods of engineered CRISPR-Cas9 systems using split-nexus Cas9-associated polynucleotides	Patent 9970026 was granted and assigned to Caribou Biosciences on May, 2018 by the United States Patent and Trademark Office.	Caribou Biosciences	Caribou Biosciences	United States Patent and Trademark Office	9970026	May 15, 2018
‌ US Patent 9970027 Compositions and methods of engineered CRISPR-CAS9 systems using split-nexus CAS9-associated polynucleotides	Patent 9970027 was granted and assigned to Caribou Biosciences on May, 2018 by the United States Patent and Trademark Office.	Caribou Biosciences	Caribou Biosciences	United States Patent and Trademark Office	9970027	May 15, 2018
‌ US Patent RE48608 Method to predict response to pharmacological chaperone treatment of diseases	Patent RE48608 was granted and assigned to Amicus Therapeutics on June, 2021 by the United States Patent and Trademark Office.	Amicus Therapeutics	Amicus Therapeutics	United States Patent and Trademark Office	RE48608	June 29, 2021
‌ US Patent 10227576 Engineered cascade components and cascade complexes	Patent 10227576 was granted and assigned to Caribou Biosciences on March, 2019 by the United States Patent and Trademark Office.	Caribou Biosciences	Caribou Biosciences	United States Patent and Trademark Office	10227576	March 12, 2019
‌ US Patent 9885026 Modified cascade ribonucleoproteins and uses thereof	Patent 9885026 was granted and assigned to Caribou Biosciences on February, 2018 by the United States Patent and Trademark Office.	Caribou Biosciences	Caribou Biosciences	United States Patent and Trademark Office	9885026	February 6, 2018
‌ US Patent 11578116 Extracellular vesicles comprising engineered fusion proteins	Patent 11578116 was granted and assigned to Diadem Biotherapeutics on February, 2023 by the United States Patent and Trademark Office.	Diadem Biotherapeutics	Diadem Biotherapeutics	United States Patent and Trademark Office	11578116	February 14, 2023
‌ US Patent 11566230 Universal donor cells	Patent 11566230 was granted and assigned to CRISPR Therapeutics on January, 2023 by the United States Patent and Trademark Office.	CRISPR Therapeutics	CRISPR Therapeutics	United States Patent and Trademark Office	11566230	January 31, 2023
‌ US Patent 12076420 Adeno-associated virus compositions for restoring PAH gene function and methods of use thereof	Patent 12076420 was granted and assigned to Homology Medicines on September, 2024 by the United States Patent and Trademark Office.	Homology Medicines	Homology Medicines	United States Patent and Trademark Office	12076420	September 3, 2024
‌ US Patent 11769073 Methods and systems for producing an expanded training set for machine learning using biological sequences	Patent 11769073 was granted and assigned to Deep Genomics (company) on September, 2023 by the United States Patent and Trademark Office.	Deep Genomics	Deep Genomics	United States Patent and Trademark Office	11769073	September 26, 2023
‌ US Patent 11326183 VCN enhancer compositions and methods of using the same	Patent 11326183 was granted and assigned to Bluebird Bio on May, 2022 by the United States Patent and Trademark Office.	Bluebird Bio	Bluebird Bio	United States Patent and Trademark Office	11326183	May 10, 2022
‌ US Patent 11786516 Methods of treating Fabry patients having renal impairment	Patent 11786516 was granted and assigned to Amicus Therapeutics on October, 2023 by the United States Patent and Trademark Office.	Amicus Therapeutics	Amicus Therapeutics	United States Patent and Trademark Office	11786516	October 17, 2023
‌ US Patent 11439971 Automated modular system and method for production of biopolymers		Synthego	Synthego	United States Patent and Trademark Office	11439971	September 13, 2022

...

Results per page:

818 results

0 selected

818 results

0 selected